NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Meridian Bioscience's Group A Streptococcus molecular diagnostic test that runs on its illumigene platform, the company said after the close of the market on Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.